Vor Biopharma (VOR) Common Equity (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Common Equity data on file, last reported at -$150.4 million in Q1 2026.

• Quarterly Common Equity fell 327.68% year-over-year to -$150.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$150.4 million (down 327.68% YoY) and the FY2025 annual result came in at -$164.3 million, down 69.98% from the prior year.
• Common Equity advanced to -$150.4 million in Q1 2026 per VOR's latest filing, from -$164.3 million in the prior quarter.
• Across five years, Common Equity topped out at $250.6 million in Q4 2022 and bottomed at -$2.2 billion in Q3 2025.
• The 5-year median for Common Equity is $123.0 million (2024), against an average of -$132.0 million.
• The widest annual swing landed in 2023, when Common Equity advanced 18.39%; it then sank 3150.49% in 2025.
• Tracing VOR's Common Equity over 5 years: stood at $250.6 million in 2022, then sank by 39.86% to $150.7 million in 2023, then sank by 164.13% to -$96.7 million in 2024, then slumped by 69.98% to -$164.3 million in 2025, then gained by 8.45% to -$150.4 million in 2026.
• Per Business Quant, the three latest VOR Common Equity figures stand at -$150.4 million (Q1 2026), -$164.3 million (Q4 2025), and -$2.2 billion (Q3 2025).

Peer Comparison